Galapagos NV
AEX:GLPG
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.12
38.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Galapagos NV
Galapagos NV
Selling, General & Administrative
Galapagos NV
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galapagos NV
AEX:GLPG
|
Selling, General & Administrative
-€187.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
M
|
MDxHealth SA
NASDAQ:MDXH
|
Selling, General & Administrative
-$92m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-15%
|
|
|
Oxurion NV
XBRU:OXUR
|
Selling, General & Administrative
-€3.8m
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Celyad Oncology SA
XBRU:CYAD
|
Selling, General & Administrative
-€4.1m
|
CAGR 3-Years
23%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Galapagos NV
Glance View
Founded in 1999, Galapagos NV emerged from the rich scientific collaboration between the Netherlands and Belgium, initially as a joint venture between the Dutch company Crucell and the Flemish biotech company Tibotec. In its early years, Galapagos carved a niche for itself by focusing on the discovery of novel targets leading to the development of human proteins for medicines. Through its proprietary technological platforms, Galapagos identifies and validates these targets, setting the stage for developing small molecules that inhibit these specific proteins. This unique approach positions the company at the forefront of innovative drug discovery, primarily targeting inflammatory diseases, fibrosis, and other conditions where there is a significant unmet medical need. Revenue for Galapagos is generated through several streams, most notably from strategic partnership deals and potential milestone payments in the biotech sector. The heart of its business model lies in deep collaborations with major pharmaceutical companies like Gilead Sciences, which bolster its financial stability and provide mutual benefits in drug development ventures. Additionally, Galapagos advances its proprietary drug candidates in clinical trials, aiming to bring them to market and secure approval from regulatory bodies. By successfully moving these candidates through clinical development phases, it stands to secure substantial future revenue from both commercialization and licensing deals. With its innovative science-focused strategy, Galapagos continues to propel forward, endeavoring to transform scientific insights into tangible therapeutic advancements.
See Also
What is Galapagos NV's Selling, General & Administrative?
Selling, General & Administrative
-187.4m
EUR
Based on the financial report for Sep 30, 2024, Galapagos NV's Selling, General & Administrative amounts to -187.4m EUR.
What is Galapagos NV's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-20%
Over the last year, the Selling, General & Administrative growth was 27%. The average annual Selling, General & Administrative growth rates for Galapagos NV have been 3% over the past three years , -20% over the past five years .
You don't have any saved screeners yet